Diagnostic and Treatment Availability of von Willebrand Disease Within Europe: Insights From a European Association for Hemophilia and Allied Disorders (EAHAD) Survey
Haemophilia · 03.11.2026
DOI: 10.1111/hae.70433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 03.11.2026. Verfasst von Omid Seidizadeh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Association for Haemophilia and Allied Disorders (EAHAD), EAHAD von Willebrand Disease Working Group, Italian Ministry of Health through the Bando Ricerca Corrente.
Abstract (Originalsprache)
Background
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, yet its diagnosis and management remain heterogeneous across Europe due to variable access to diagnosis and care.
Aim
To characterize diagnostic and treatment practices for VWD across European hemophilia centers.
Methods
The European Association for Haemophilia and Allied Disorders (EAHAD) VWD Working Group conducted a cross‐sectional online survey among affiliated centers to evaluate center characteristics, use of bleeding assessment tools (BATs), availability of laboratory assays, genetic testing practices, diagnostic algorithms, and access to care and monitoring of treatments.
Results
Sixty‐two centers (27 countries) participated, being mostly comprehensive hemophilia care centers (77%). BATs were used by 85% of centers. Variability of VWF levels (57%) and limited access to genetic testing (29%) were the most frequently reported diagnostic challenges. VWF:Ag and FVIII:C assays were widely available (98%), whereas multimer analysis (39%), VWF:FVIIIB (31%), and VWFpp testing (13%) were less accessible. Genetic testing was performed routinely or selectively by 89%, most commonly using targeted next‐generation sequencing panels (65%). A VWF activity‐to‐antigen ratio threshold of 0.7 was used by 65% of centers to distinguish type 1 from type 2 VWD. While plasma‐derived VWF/FVIII concentrates were universally available, access to recombinant VWF (rVWF) was limited, with approximately one‐third of centers reporting no access. Prophylaxis was used predominantly for type 3 (78%) and cases with severe bleeding phenotypes regardless of subtype (63%).
Conclusions
Disparities in VWD diagnosis and care persist across Europe, highlighting the need for harmonized pathways and equitable access to specialized testing and therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
- Department of Internal Medicine, Haemophilia Center, University Hospital Centar Zagreb, University of Zagreb Medical School, Zagreb, Croatia.
- Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals, Oxford, Oxfordshire, UK.
- Coagulation Disorders Unit, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Department of Hemostasis and Transfusion, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, INSERM, University of Lille, Lille, France.
- Institute of Experimental Haematology and Transfusion Medicine, Medical Faculty, University of Bonn, Bonn, Germany.
Förderung
- European Association for Haemophilia and Allied Disorders (EAHAD)
- EAHAD von Willebrand Disease Working Group
- Italian Ministry of Health through the Bando Ricerca Corrente
Zitieren
APA
Seidizadeh, O., Boban, A., Shapiro, S., Lassila, R., Susen, S., Yadegari, H., Lorenzo, L. Q., O'Donnell, J. S., Castaman, G., Eikenboom, J., & EAHAD von Willebrand Disease Working Group (2026). Diagnostic and Treatment Availability of von Willebrand Disease Within Europe: Insights From a European Association for Hemophilia and Allied Disorders (EAHAD) Survey. Haemophilia. https://doi.org/10.1111/hae.70433
Vancouver
Seidizadeh O, Boban A, Shapiro S, Lassila R, Susen S, Yadegari H, et al. Diagnostic and Treatment Availability of von Willebrand Disease Within Europe: Insights From a European Association for Hemophilia and Allied Disorders (EAHAD) Survey. Haemophilia. 2026. doi:10.1111/hae.70433
BibTeX
@article{Seidizadeh2026,
author = {Seidizadeh, Omid and Boban, Ana and Shapiro, Susie and Lassila, Riitta and Susen, Sophie and Yadegari, Hamideh and Lorenzo, Laura Quintas and O'Donnell, James S and Castaman, Giancarlo and Eikenboom, Jeroen and EAHAD von Willebrand Disease Working Group, EAHAD von Willebrand Disease Working Group},
title = {Diagnostic and Treatment Availability of von Willebrand Disease Within Europe: Insights From a European Association for Hemophilia and Allied Disorders (EAHAD) Survey},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70433}
}
EUVIMED